Breathe better

Live better

Empowering you to take charge of your airways, one breath at a time.

Feno testing is a quick, simple, non-invasive way to uncover hidden swelling in your airways, giving you and your doctor a clearer picture of what is happening in your lungs.¹

It's not just a test. It's an opportunity.

What is feno?

Asthma affects millions of people worldwide.²

What's even more surprising is that it's estimated that up to 73% of people may have asthma without knowing it, meaning airway swelling could be building without them realising - putting them at risk of serious attacks.^3-5

All about asthma

Feno stories

Read our real patient stories and experiences on how feno testing helped with their condition. From clarity with diagnosis, validating their struggles, to understanding their condition for better outcomes.

Meet Nadia

How FeNO Testing Led to an Accurate Asthma Diagnosis and Changed Her Life¹

Meet Ben

How FeNO Testing Led to the Right Diagnosis for Breathing Issues

Meet Leila

How FeNO Testing Helped Confirm Asthma in a Young Child¹

Meet Amina

How FeNO testing transformed how she lives with asthma

Meet Ethan

How FeNO Testing Helped Him Prepare for the Army Safely

Swipe to see more stories

Be informed. Be empowered.

About us

We believe everyone with respiratory conditions deserves access to the right tools and information.
That’s why feno for me is dedicated to raising awareness of feno testing and its role in improving asthma care.
We want to empower people with asthma through awareness, education and action.

References:

1. Alving K et al. Validation of a new portable exhaled nitric oxide analyzer, NIOX VERO®: randomized studies in asthma. Pulm Ther. 2017;3:207-18.

2. Global Initiative for Asthma (GINA). 2026 GINA Strategy Report; Global strategy for asthma management and prevention. Available at; https://ginasthma.org/2026-gina-strategy-report/

3. Kavanagh J et al. Over- and under-diagnosis in asthma. Breathe (Sheff). 2019;15(1):e20-e27.

4. Busse W et al. Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis. The Lancet Respiratory Medicine. 2021;9(10):1165-73.

5. Meulmeester F et al. Inflammatory and clinical risk factors for asthma attacks (ORACLE2): a patient-level meta-analysis of control groups of 22 randomised trials. The Lancet Respiratory Medicine. 2025 Apr 8.